단백질체학 시장 : 전략적 인사이트와 예측(2026-2031년)

The Global Proteomics Market is projected to expand from USD 40.9 billion in 2026 to USD 61.8 billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.6%.

The global proteomics market represents a critical segment of modern life sciences research and biomedical innovation. Proteomics focuses on the large-scale study of proteins, including their structure, function, and interactions within biological systems. As proteins directly influence cellular processes and disease mechanisms, proteomics has become an essential analytical platform for pharmaceutical research, clinical diagnostics, and biomarker discovery. Advances in analytical technologies and computational biology have expanded the ability to analyze complex protein structures and modifications at high resolution. These capabilities are enabling researchers to understand disease pathways and identify therapeutic targets more effectively. The increasing integration of proteomics with genomics, transcriptomics, and bioinformatics is transforming the field into a comprehensive multi-omics research platform. This shift is expanding the role of proteomics from basic academic research to practical applications in precision medicine, drug discovery, and clinical diagnostics.

Market Drivers

One of the primary drivers of the proteomics market is the increasing investment in life sciences research. Governments, research institutions, and private pharmaceutical companies are allocating substantial funding to biomedical research programs that rely heavily on proteomic analysis. Large-scale initiatives focusing on human proteome mapping and disease biomarker discovery are accelerating demand for high-performance analytical instruments and reagents.

Another significant growth factor is the rising importance of personalized medicine. Modern healthcare strategies increasingly emphasize individualized treatment approaches based on genetic and molecular characteristics. Proteomics enables the identification of protein biomarkers that reveal disease progression, drug response, and patient-specific biological conditions. These insights support targeted therapies and precision diagnostics, thereby increasing demand for advanced proteomic technologies in pharmaceutical and clinical research environments.

Technological advancements in mass spectrometry and high-throughput analysis platforms are also contributing to market expansion. Modern proteomics instruments offer improved sensitivity, faster data acquisition, and the ability to identify low-abundance proteins and post-translational modifications. These capabilities are critical for understanding complex biological processes and disease mechanisms, further strengthening adoption of proteomic tools across research laboratories and biotechnology companies.

Market Restraints

Despite strong growth potential, the proteomics market faces several operational challenges. One of the most significant constraints is the high capital investment required for advanced analytical instruments such as high-resolution mass spectrometers. The cost of acquiring and maintaining these systems can be prohibitive for smaller research institutions and early-stage biotechnology firms.

Another challenge is the technical complexity associated with proteomics research. Proteomic data analysis requires specialized expertise in bioinformatics, statistics, and computational biology. The shortage of skilled professionals capable of interpreting complex datasets can limit the widespread adoption of proteomics technologies in certain research environments.

Technology and Segment Insights

The global proteomics market is segmented by technology, component, application, and geography. Key technologies include microarrays, spectroscopy, chromatography, and X-ray crystallography. Among these, mass spectrometry-based platforms dominate the market due to their ability to identify and quantify proteins with high precision and sensitivity.

By component, the market includes reagents and kits, consumables, and instruments. Reagents and consumables account for a significant share of market revenue because they are required continuously for sample preparation, labeling, and protein analysis workflows. Their recurring usage creates stable demand across academic research laboratories and pharmaceutical companies.

Application-wise, the discovery of protein biomarkers represents a major segment of the market. Proteomic analysis enables researchers to identify disease-specific protein signatures that can serve as diagnostic indicators or therapeutic targets. These applications are particularly important in oncology, neurology, cardiovascular disease research, and infectious disease studies.

Geographically, North America maintains a leading position due to strong research funding, advanced laboratory infrastructure, and the presence of major biotechnology and pharmaceutical companies. Asia Pacific is also emerging as a high-growth region as governments invest heavily in biomedical research and pharmaceutical innovation.

Competitive and Strategic Outlook

The competitive landscape of the proteomics market includes major analytical instrument manufacturers, biotechnology firms, and specialized reagent suppliers. Companies differentiate themselves through technological innovation, instrument performance, and integrated workflow solutions that combine hardware, reagents, software, and data analysis services.

Strategic collaborations between pharmaceutical companies, academic institutions, and technology providers are becoming increasingly common. These partnerships enable the development of advanced proteomic platforms and facilitate large-scale research projects focused on biomarker discovery and therapeutic development.

Additionally, many companies are expanding service offerings through contract research organizations and specialized analytical laboratories. Outsourced proteomics services allow researchers to access sophisticated analytical capabilities without investing in expensive instrumentation.

Key Takeaways

The global proteomics market is expected to experience sustained growth as the demand for advanced molecular analysis technologies continues to rise. Expanding research investments, the increasing adoption of precision medicine, and continuous advancements in analytical instrumentation are driving the development of the market. Although high equipment costs and technical complexity remain challenges, ongoing technological innovation and the integration of proteomics with other omics platforms are expected to expand its applications across biomedical research and clinical diagnostics.

Key Benefits of this Report

• Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What businesses use our reports for

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2025 and forecast data from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL PROTEOMICS MARKET BY TECHNOLOGY

• 5.1. Introduction
• 5.2. Microarrays
• 5.3. Spectroscopy
• 5.4. X-Ray Crystallography
• 5.5. Chromatography
• 5.6. Others

6. GLOBAL PROTEOMICS MARKET BY COMPONENT

• 6.1. Introduction
• 6.2. Reagents & Kits
• 6.3. Consumables
• 6.4. Others

7. GLOBAL PROTEOMICS MARKET BY REAGENTS

• 7.1. Introduction
• 7.2. Microarrays Reagents
• 7.3. Spectroscopy Reagents
• 7.4. X-Ray Crystallography Reagents
• 7.5. Chromatography Reagents
• 7.6. Other Reagents

8. GLOBAL PROTEOMICS MARKET BY APPLICATION

• 8.1. Introduction
• 8.2. Discovery of Protein Biomarkers
• 8.3. Study of Tumor Metastasis
• 8.4. Neurotrauma and Neurology
• 8.5. Renal Disease Diagnosis
• 8.6. Fetal and Maternal Medicine
• 8.7. Others

9. GLOBAL PROTEOMICS MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. United States
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. Germany
  • 9.4.2. France
  • 9.4.3. United Kingdom
  • 9.4.4. Others
• 9.5. Middle East & Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. Japan
  • 9.6.3. South Korea
  • 9.6.4. India
  • 9.6.5. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Biognosys AG
• 11.2. Creative Proteomics (Division of Creative Dynamics Inc)
• 11.3. Proteomics International
• 11.4. MRM Proteomics
• 11.5. Evotec AG
• 11.6. Proteome Factory
• 11.7. DC Biosciences
• 11.8. AYOXXA Biosystems GmbH
• 11.9. VProteomics
• 11.10. Thermo Fisher Scientific
• 11.11. Agilent Technologies

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations